At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 118 enrolled
Drug / intervention
LY2228820 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating LY2228820, Carboplatin, and 2 other interventions for Epithelial Ovarian Cancer and 2 related conditions. Completed, enrolled 118 participants across 30 sites in 4 countries.
Detailed Summary
A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, Germany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedAug 2012
Primary CompletionMay 2017
Study CompletionMay 2018
TodayJul 2026
First PostedAug 13, 2012
Enrollment StartJul 1, 2012
Primary CompletionMay 25, 2017
Study CompletionMay 11, 2018
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 13.9 years ago
Interventions
LY2228820drug
Administered Orally
Carboplatindrug
Administered IV
Placebodrug
Administered Orally
Gemcitabinedrug
Administered IV